Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 8/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | BCR | P11274 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907246 | 0.87 | GAA (0.37) | KDRPDGFRBPTPN11 | |
| SCHEMBL15907316 | 0.85 | CSF1R (0.35) | KDRPDGFRBLCKTEKPTPN11 | |
| SCHEMBL15907286 | 0.79 | HTT (0.36) | KDRPDGFRBIKBKBPTPN11 | |
| SCHEMBL15907302 | 0.77 | IKBKB (0.46) | KDRPDGFRBLCKTEKIKBKB | |
| SCHEMBL18323164 | 0.74 | IKBKB (0.41) | KDRPDGFRBLCKTEKIKBKB | |
| SCHEMBL15907309 | 0.72 | CSF1R (0.37) | ABL1CSF1R | |
| SCHEMBL15907278 | 0.72 | PDE4B (0.33) | ABL1CSF1R | |
| SCHEMBL15907264 | 0.69 | ABL1 (0.36) | KDRLCKTEKABL1CSF1R | |
| SCHEMBL15907307 | 0.68 | CSF1R (0.40) | KDRPDGFRBLCKTEKABL1 | |
| SCHEMBL18323145 | 0.68 | ALDH1A1 (0.47) | KDRPDGFRBLCKTEKIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KDR 676/4885PDGFRB 831/4885LCK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.